Symbols

PRCT

PROCEPT BioRobotics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 5

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PRCT

Procept Biorobotics Corporation

A medical robotics company that develops and commercializes innovative surgical robots and instruments for urology and other medical specialties

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

09/15/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

756

Fiscal Year Ends

12-31

Website

www.procept-biorobotics.com

Security Type

Common stock

Office address

150 Baytech Drive, San Jose, CA 95134

Business

Introduction

PROCEPT BioRobotics Corporation was incorporated in California in 2007. In April 2021, the company was re-incorporated in Delaware. The company is a commercial stage surgical robotics company focused on advancing patient care by developing transformative solutions for urology. They develop, manufacture and market the AquaBeam Robotic System, an advanced image-guided surgical robotic system for minimally invasive urological surgery, initially focused on the treatment of benign prostatic hyperplasia, or BPH.

Earnings Call

Q2/2025

Estimate EPS-0.41

Actual EPS-0.35

Estimate Revenue76.24M

Actual Revenue79.20M

Contradictions in Financial Guidance: Examining Market Growth, Tariffs, and Procedure Volumes in Recent Earnings Calls

Aug 11,2025 10:26·
Earnings Decrypt

Company Financials

EPS

PRCT has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.42, beating expectations. The chart below visualizes how PRCT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PRCT has released its 2025 Q3 earnings report, with revenue of 83.33M, reflecting a YoY change of 42.76%, and net profit of -21.41M, showing a YoY change of -2.08%. The Sankey diagram below clearly presents PRCT's revenue sources and cost distribution.